|
Press Releases |
|
|
|
Wednesday, March 23, 2022 |
|
Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities |
Singapore Exchange-listed Alset International Ltd (SGX Stock Code: 40V) ("Alset", the "Company" or together with its subsidiaries, the "Group) wishes to announce that the Company has plans to embark on cryptocurrency mining business through its subsidiary Alset Mining Pte. Ltd. ("Alset Mining"). more info >> |
|
Monday, February 21, 2022 |
|
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option |
Alset Capital Acquisition Corp. (the "Company") announced on February 3, 2022 the closing of its initial public offering of 7,500,000 units at $10.00 per unit (the "Offering"). more info >> |
|
Monday, October 5, 2020 |
|
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc. |
Document Security Systems, Inc. today announced its wholly owned subsidiary Impact BioMedical, Inc. ("Impact BioMedical") has formed a new wholly owned subsidiary, Innate Immune, Inc. ("Innate Immune"), to initiate efficacy testing of a pancoronavirus vaccine, a special type of vaccine designed to protect against multiple coronaviruses. more info >> |
|
Friday, September 18, 2020 |
|
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance |
Document Security Systems, Inc. (NYSE American: DSS) today announced its wholly owned subsidiary Impact BioMedical, Inc., through its subsidiary Global BioLife, Inc., completed efficacy testing of its proprietary 3F Antiviral Biofragrance at a biosafety level 3 containment facility at an independent university. more info >> |
|
Friday, July 31, 2020 |
|
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development |
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly-owned subsidiary Impact Biomedical Inc. ("Impact"), announced today the initiation of Quantum, their research program designed to solve the impending pharmaceutical patent cliff threat. more info >> |
|
Wednesday, June 24, 2020 |
|
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance |
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that they proved in vitro success of Equivir and 3F Biofragrance against COVID-19 in independent laboratory testing. more info >> |
|
Wednesday, June 17, 2020 |
|
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal |
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that their COVID-19 research with Global Research and Discovery Group Sciences ("GRDG"), conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. ("Vilotos"), was published in the peer-reviewed scientific journal Molecules on June 11, 2020. more info >> |
|
Monday, June 1, 2020 |
|
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts |
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary, Impact Biomedical Inc., would like to update its stakeholders on its suite of antiviral and medical technologies. more info >> |
|
Friday, April 24, 2020 |
|
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts |
SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced recently that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million). more info >> |
|
Wednesday, March 18, 2020 |
|
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak |
Singapore Exchange-listed Singapore eDevelopment Limited has announced that its wholly-owned U.S. biomedical subsidiary, Impact BioMedical, Inc., has, through its scientific research partner, GRDG Sciences, LLC. ("GRDG"), recently conducted molecular docking studies, utilizing advanced computational models, which indicate Linebacker and Equivir successfully inhibit infection of SARS-CoV-2, the virus responsible for the COVID-19 outbreak. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
锅圈:持续扩大业务规模 盈利能力持续增强
Mar 29, 2024 18:10 HKT/SGT
|
|
|
鍋圈:持續擴大業務規模 盈利能力持續增強
Mar 29, 2024 18:07 HKT/SGT
|
|
|
Guoquan: Continuously Expanding the Business Scale While Enhancing Profitability
Mar 29, 2024 18:02 HKT/SGT
|
|
|
直面企业发展转型挑战 联想控股如何发展新质生产力
Mar 29, 2024 17:14 HKT/SGT
|
|
|
直面企業發展轉型挑戰 聯想控股如何發展新質生產力
Mar 29, 2024 17:10 HKT/SGT
|
|
|
联想控股2023年收入4360亿元
Mar 29, 2024 17:05 HKT/SGT
|
|
|
聯想控股2023年收入4360億元
Mar 29, 2024 17:01 HKT/SGT
|
|
|
Legend Holdings Realized Revenue of RMB436 billion in 2023
Mar 29, 2024 16:55 HKT/SGT
|
|
|
Panasonic Energy and Mazda Enter Agreement Towards Supply of Cylindrical Automotive Lithium-ion Batteries
Mar 29, 2024 17:42 JST
|
|
|
Gome Retail Streamlines to Focus on Main Business
Mar 29, 2024 16:07: JST
|
|
|
Gome Fin Tech Announced Annual Results of 2023
Mar 29, 2024 15:36: JST
|
|
|
国美零售瘦身聚焦主业
Mar 29, 2024 15:20 HKT/SGT
|
|
|
國美零售瘦身聚焦主業
Mar 29, 2024 15:15 HKT/SGT
|
|
|
Gome Retail Streamlines to Focus on Main Business
Mar 29, 2024 15:07 HKT/SGT
|
|
|
国美金融科技公布2023年度业绩
Mar 29, 2024 14:53 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|